SCHEMBL18989121

SCHEMBL18989121

CCOC(=O)c1cnc(N2CC(NC(=O)OC(C)(C)C)C2)o1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 1/20 0.41
BTK Q06187 1/20 0.41
CKS1B P61024 1/20 0.40
SKP1 P63208 1/20 0.40
SKP2 Q13309 1/20 0.40
NLRP3 Q96P20 2/20 0.39
PDE10A Q9Y233 2/20 0.38
RET P07949 1/20 0.38
KMT2A Q03164 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAP4K4 O95819 2/20 0.37
PDE2A O00408 1/20 0.37
PIK3CD O00329 2/20 0.37
GAA P10253 1/20 0.37
CTSK P43235 2/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18988192 0.89 CKS1B (0.50) JAK3BTKCKS1BSKP1SKP2
SCHEMBL1012386 0.80 ACACB (0.48) JAK3BTKCKS1BSKP1SKP2
SCHEMBL18987724 0.79 NLRP3 (0.41) NLRP3KMT2AL3MBTL1MAP4K4GAA
SCHEMBL2822395 0.77 OGA (0.43) JAK3BTKCKS1BSKP1SKP2
SCHEMBL20163057 0.76 GPR119 (0.47) CKS1BSKP1SKP2KMT2AGAA
SCHEMBL3922100 0.75 P2RY12 (0.62)
SCHEMBL21227951 0.75 JAK3 (0.43) JAK3BTKCKS1BSKP1SKP2
SCHEMBL12491653 0.74 NLRP3 (0.49) NLRP3
SCHEMBL17869189 0.74 KMT2A (0.46) NLRP3KMT2AL3MBTL1
SCHEMBL19020299 0.73 CKS1B (0.51) JAK3BTKCKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3390384-B1 QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS ASTEX THERAPEUTICS LTD (GB) 2021-09-15 EP disclosed
EP-3390384-B1 QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS ASTEX THERAPEUTICS LTD (GB) 2021-09-15 EP disclosed
US-20210238162-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-08-05 US disclosed
US-20210238162-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-08-05 US disclosed
EP-3390384-A1 QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS Astex Therapeutics Limited (GB) 2018-10-24 EP disclosed
WO-2017103851-A1 QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2017-06-22 WO disclosed
WO-2017103851-A1 QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2017-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238162-A1 CHEMICAL COMPOUNDS HPGDS, PTGS1, PTGIS JAK3 2549/4885BTK 4035/4885CKS1B 357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.